Lallemand Pharma

Lallemand Pharma is a specialized pharmaceutical company focused on the development and commercialization of bacterial lysates for the prevention and treatment of respiratory tract infections. As a division of the global yeast and bacteria leader Lallemand, the company leverages proprietary mechanical lysis technology to produce immunomodulatory products that stimulate both innate and adaptive immunity. Its flagship product, Ismigen, is a polyvalent mechanical bacterial lysate (PMBL) used globally to reduce the incidence and severity of recurrent respiratory infections in both children and adults. The company's portfolio targets conditions such as chronic obstructive pulmonary disease (COPD) and chronic bronchitis, positioning it as a key player in mucosal immunity and respiratory health.